DMDiana Mikiewicz

Diana Mikiewicz

*This is an algorithmically generated author record based on publicly available information.

Diana Mikiewicz has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gene expression, purification, and functional characterization of recombinant conotoxin μ-TIIIA and TIIIAlaMut in Escherichia coli with clinical evaluation of antiwrinkle efficacy

    by Diana Mikiewicz, Anna Mazurkiewicz-Pisarek, Magdalena Janczewska, Jolien De Waele, Alina Mazurkiewicz, Agata Stefanek, Frank Bosmans, Agnieszka Lew-Mirska, Przemysław Styczeń, Tomasz Ciach

    Background: Conotoxins are small peptides known for their potent and selective activity on ion channels, offering potential applications in both medicine and cosmetology. This study aimed to design and validate recombinant conotoxins (TIIIA and its mutant TIIIAlaMut), assess their biological activity on Nav1.4 sodium channels, and evaluate the anti-wrinkle efficacy of a topical cream containing the recombinant peptide in a group of volunteers. Material and methods: Fusion genes encoding TRX::TIIIA and TRX::TIIIAlaMut were cloned into the pDM vector and expressed in Escherichia coli S4B cells. The proteins were purified using Ni-NTA chromatography, cleaved with CNBr under optimized acidic conditions, and analyzed. Biological activity was tested using patch-clamp electrophysiology in Xenopus laevis oocytes expressing Nav1.4 channels. Additionally, the conotoxin-containing cream was applied by 55 human volunteers in an application study assessing anti-aging effects. Results: Both recombinant peptides were expressed, purified, and activated. Electrophysiological measurements demonstrated their ability to modulate Nav1.4 channel activity, including the version extracted from the cream. In the human study, 47% of participants reported visible reduction of wrinkles. Additional benefits included skin tone evening, erythema reduction, and balanced sebum production in oily skin types. Conclusions: This study describes the design, bacterial expression, and functional analysis of recombinant conotoxins TIIIA and TIIIAlaMut. Their bioactivity was confirmed on Xenopus laevis oocytes expressing human Nav 1.4 channels. The recombinant toxins, including one extracted from a cream, showed effects comparable to a synthetic standard. Application tests demonstrated the conotoxin’s potential in cosmeceuticals, especially in reducing periocular wrinkles and improving skin texture and tone.


  • Open Access

    Bacterial expression and characterization of an anti-CD22 single-chain antibody fragment

    by Diana Mikiewicz, Natalia Łukasiewicz, Marcin Zieliński, Violetta Cecuda-Adamczewska, Anna Bierczyńska-Krzysik, Agnieszka Romanik-Chruścielewska, Małgorzata Kęsik-Brodacka


  • Open Access

    Novel Expression Vectors Based on the pIGDM1 Plasmid

    by Diana Mikiewicz, Andrzej Plucienniczak, Anna Bierczynska-Krzysik, Agnieszka Skowronek, Grzegorz Wegrzyn

    Escherichia coli is one of the most widely used hosts for the production of heterologous proteins. Within this host, the choice of cloning vector constitutes a key factor for a satisfactory amplified expression of a target gene. We aimed to develop novel, unpatented expression vectors that enable the stable maintenance and efficient overproduction of proteins in E. coli. A series of expression vectors based on the ColE1-like pIGDM1 plasmid were constructed. The vectors named pIGDMCT7RS, pIGDM4RS and pIGDMKAN carry various antibiotic resistance genes: chloramphenicol, ampicillin or kanamycin, respectively. Two derivatives contain the inducible T7 promoter while the third one bears the constitutive pms promoter from a clinical strain of Klebsiella pneumoniae. The pIGDM1-derivatives are compatible with other ColE1-like plasmids commonly used in molecular cloning. The pIGDMCT7RS and pIGDM4RS vectors contain genes encoding AGA and AGG tRNAs, which supplement the shortage of these tRNAs, increasing the efficiency of synthesis of heterologous proteins. In conclusion, pIGDMCT7RS, pIGDM4RS and pIGDMKAN vectors, with significantly improved features, including compatibility with vast majority of other plasmids, were designed and constructed. They enable a high-level expression of a desired recombinant gene and therefore constitute a potential, valuable tool for pharmaceutical companies and research laboratories for their own research or for the production of recombinant biopharmaceuticals.


  • Open Access

    Expression and purification of recombinant human insulin from E. coli 20 strain

    by Marcin Zieliński, Agnieszka Romanik-Chruścielewska, Diana Mikiewicz, Natalia Łukasiewicz, Iwona Sokołowska, Jarosław Antosik, Agnieszka Sobolewska-Ruta, Anna Bierczyńska-Krzysik, Piotr Zaleski, Andrzej Płucienniczak


  • Open Access

    Soluble insulin analogs combining rapid- and long-acting hypoglycemic properties – From an efficient E. coli expression system to a pharmaceutical formulation

    by Diana Mikiewicz, Anna Bierczyńska-Krzysik, Agnieszka Sobolewska, Dorota Stadnik, Monika Bogiel, Monika Pawłowska, Anna Wójtowicz-Krawiec, Piotr A Baran, Natalia Łukasiewicz, Agnieszka Romanik-Chruścielewska, et al.

    The discovery of insulin led to a revolution in diabetes management. Since then, many improvements have been introduced to insulin preparations. The availability of molecular genetic techniques has enabled the creation of insulin analogs by changing the structure of the native protein in order to improve the therapeutic properties. A new expression vector pIBAINS for production of four recombinant human insulin (INS) analogs (GKR, GEKR, AKR, SR) was constructed and overexpressed in the new E. coli 20 strain as a fusion protein with modified human superoxide dismutase (SOD). The SOD gene was used as a signal peptide to enhance the expression of insulin. SOD::INS was manufactured in the form of insoluble inclusion bodies. After cleavage of the fusion protein with trypsin, the released insulin analogs were refolded and purified by reverse-phase high performance liquid chromatography (RP-HPLC). Elongation of chain A, described here for the first time, considerably improved the stability of the selected analogs. Their identity was confirmed with mass spectrometric techniques. The biological activity of the insulin derivatives was tested on rats with experimental diabetes. The obtained results proved that the new analogs described in this paper have the potential to generate prolonged hypoglycemic activity and may allow for even less frequent subcutaneous administration than once-a-day. When applied, all the analogs demonstrate a rapid onset of action. Such a combination renders the proposed biosynthetic insulin unique among already known related formulations.


  • Expression of recombinant human bifunctional peptidylglycine α-amidating monooxygenase in CHO cells and its use for insulin analogue modification

    by Marcin Zieliński, Anna Wójtowicz-Krawiec, Diana Mikiewicz, Małgorzata Kęsik-Brodacka, Violetta Cecuda-Adamczewska, Alina Marciniak-Rusek, Iwona Sokołowska, Natalia Łukasiewicz, Lidia Gurba, Michał Odrowąż-Sypniewski, et al.


  • Open Access

    Use of Ubp1 protease analog to produce recombinant human growth hormone in Escherichia coli

    by Anna Wojtowicz-Krawiec, Iwona Sokolowska, Maria Smorawinska, Luiza Chojnacka-Puchta, Diana Mikiewicz, Natalia Lukasiewicz, Alina Marciniak-Rusek, Renata Wolinowska, Anna Bierczynska-Krzysik, Anna Joanna Porebska, et al.

    Numerous bacterial human growth hormone (hGH) expression methods under conventional fermentation and induction conditions have been described. Despite significant progress made in this area over the past several years, production of recombinant hGH by using cellular expression systems still requires further optimization. Fusion of the ubiquitin (Ub) tag to the hGH protein allowed to increase of the overall efficiency of the biosynthesis and improve the protein stability. Ub is a protein composed of 76 amino acid residues with a molecular mass of 8.6 kDa, expressed in all eukaryotes. This protein is an element of the universal protein modification system, which does not occur in bacteria, and is a useful carrier for heterologous proteins obtained through expression in Escherichia coli. Purification of Ub-fusion proteins is easier than that of unconjugated recombinant proteins, and Ub can be removed by deubiquitinating proteases (DUBs or UBPs). In the present study the UBPD2C protease, a stable UBP1 analog, was produced as a recombinant protein in E. coli and used for production of recombinant human growth hormone (rhGH). hGH was expressed as a fusion protein with Ub as a tag. Our findings show that the UBPD2C protease is very effective in removing the Ub moiety from recombinant Ub-fused hGH. The described approach enables obtaining a considerable yield of rhGH in a purity required for pharmaceutical products.


  • Biosynthetic engineered B28K–B29P human insulin monomer structure in water and in water/acetonitrile solutions

    by Piotr Borowicz, Wojciech Bocian, Jerzy Sitkowski, Elżbieta Bednarek, Diana Mikiewicz-Syguła, Dariusz Kurzynoga, Dorota Stadnik, Weronika Surmacz-Chwedoruk, Wiktor Koźmiński, Lech Kozerski


  • New cloning and expression vector derived from Escherichia coli plasmid pIGWZ12; A potential vector for a two-plasmid expression system

    by Piotr Zaleski, Pawel Wawrzyniak, Agnieszka Sobolewska, Diana Mikiewicz, Anna Wojtowicz-Krawiec, Luiza Chojnacka-Puchta, Marcin Zielinski, Grazyna Plucienniczak, Andrzej Plucienniczak


  • Open Access

    A novel system for stable, high-level expression from the T7 promoter

    by Malgorzata Kesik-Brodacka, Agnieszka Romanik, Diana Mikiewicz-Sygula, Grazyna Plucienniczak, Andrzej Plucienniczak

    The most widespread, efficient prokaryotic protein-producing system is one where the T7 phage polymerase recognizes the T7 phage promoter (T7 p/p system). Unfortunately, in this system, target protein expression gradually declines and is often undetectable following 3 to 5 subcultures. Although a number of studies have attempted to stabilize the expression levels of the T7 p/p system, none has resolved the problem adequately and thus precludes the use of this system for the production of recombinant proteins on a large scale.